ArticleTransplantation direct2026
MicroRNA Profiling as a Novel Predictive Tool for Operational Tolerance in Pediatric Liver Transplantation: A Single-center Study.
Article in Transplantation direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to identify serum microRNAs (miRNA) as a predictive tool for operational tolerance in pediatric liver transplantation (LT). Methods: Pediatric LT recipients were included in an immunosuppressant (IS) minimization protocol in our institution. Blood samples were collected at 2 stages: pre-protocol and post-completion. Ninety miRNAs expression was analyzed from blood samples using the NextAmp Analysis System and mirSCAN PanelChip (Quark Biosciences, Inc.). Participants were categorized into 3 groups: IS-free (complete withdrawal), IS-high (serum tacrolimus level > 2 ng/mL), and IS-low (serum tacrolimus level ≤ 2 ng/mL). Results: Between 2011 and 2019, 37 patients were enrolled in the IS minimization protocol at Taipei Veterans General Hospital. Of these, 13 patients (35.1%) successfully achieved IS-free status, whereas 24 (64.8%) remained non-IS-free. Eighteen patients with blood samples at pre-protocol and post-completion stage were included in the analysis. A total of 27 miRNAs exhibited significant differences in expression between the IS-free and IS-high groups at the pre-protocol stage. Additionally, 13 miRNAs showed significant changes in expression between the pre-protocol and post-completion stages in the IS-free group. miRNAs associated with immune suppression were expressed at higher levels in the IS-high group and at lower levels in the IS-free group at the pre-protocol stage. Conclusions: In this study, we identified 6 miRNAs-hsa-miR-21-5p, hsa-miR-22-3p, hsa-miR-30c-5p, hsa-miR-181b-5p, hsa-miR-20a-5p, and hsa-miR-125b-5p-that predict operational tolerance in pediatric LT at both the pre-protocol stage and during the minimization period. Notably, hsa-miR-125b-5p demonstrated perfect discriminative performance at the pre-protocol stage (area under the curve 1.00; sensitivity 100%; and specificity 100%) and showed significant changes in ΔCq between the pre-protocol and post-completion stages in the IS-free group. To our knowledge, this is the first report of miRNA biomarkers exhibiting such high accuracy for identifying operational tolerance in pediatric LT.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.